CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder

CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder

Here we report 3 cases of neuromyelitis optica spectrum disorder (NMOSD), who were all treated with eculizumab and could be observed with monitoring serum C3, C4 and 50% hemolytic complement (CH50) before and after the treatment. Serum C3 and C4 were not dramatically changed during the treatment, in...

Full description

Bibliographic Details
Main Authors: Chihiro Namatame, Tatsuro Misu, Yoshiki Takai, Shuhei Nishiyama, Ichiro Nakashima, Kazuo Fujihara, Masashi Aoki
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Heliyon
Subjects:
Neuromyelitis Optica
Neuromyelitis optica spectrum disorder
Eculizumab
Biomarker
CH50
50% hemolytic complement
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844021000049

Similar Items

Similar Items